Authors
Latest:
FDA Approves Ensifentrine, Novel Treatment for Chronic Obstructive Pulmonary DiseaseOn June 26, 2024, the FDA approved ensifentrine (Ohtuvayre) for the treatment of COPD.
Latest:
Asembia Does a Great Job Bringing Professionals Together, Experts Say | Asembia 2025The Summit provides a rare opportunity for professionals to dive deep into emerging healthcare technologies and treatment models.
Latest:
COVID-19 Omicron Variant Associated with Lower Risk of Severe Illness vs Delta VariantVaccination greatly reduces the probability of experiencing severe COVID-19 in both variants. Adults between the ages of 40 to 59 years saw the most significant reduction in risk when compared to individuals in other age categories.
Latest:
Assessing Medicaid Policy Barriers to Gene, Cell TherapiesResearchers of a new paper discuss the inconsistencies between gene and cell therapy indications and payor coverage.
Latest:
The Chronic Complications For Children With T1DMPart of the risk of developing kidney involvement begins when type 1 diabetes mellitus (T1DM) sets in and establishes itself in the patient, with up to 65% of children experiencing acute kidney injury during T1DM onset, which can further predispose to the development of future chronic kidney disease.
Latest:
Combining Keytruda And Chemo May Improve Survival in Advanced Endometrial CancerPatients with advanced or recurrent endometrial cancer treated with Keytruda plus chemotherapy had improved progression-free survival compared with chemotherapy alone.
Latest:
Ethical, Practical Considerations of Exemptions to Employer Vaccine Mandates for AnxietyDoes anxiety justify an exemption from vaccine mandates among health care workers?
Latest:
Fertility Treatments Equally Effective in Women With, Without PCOSWomen with PCOS were more likely to begin fertility treatment with ovulation induction compared to those without PCOS.
Latest:
Challenges Facing Healthcare: The Unvaccinated COVID-19 PatientDo no harm, even though your patient might.
Latest:
Wicked Good Cardiometabolic Chat: Compounded Weight Loss MedicationsIn the first episode of the podcast, Jennifer Goldman and Hailey Choi discuss the latest FDA updates around compounded weight loss medications, clinical concerns and how pharmacists can protect their patients.
Latest:
New Drug Approvals in PediatricsThis past year has seen several important new drug approvals and labeling updates for children. Here is what you should know.
Latest:
Advanced Hybrid Closed-Loop Technology Could Improve Quality of Life in Type 1 DiabetesA 1-year observational follow-up of a 3-month randomized controlled trial provides insight into the benefits of advanced hybrid closed-loop system use in people with type 1 diabetes using multiple daily injections and self-monitoring of blood glucose.
Latest:
Many People Still Unaware Of Telehealth's EfficacyDespite telehealth’s rise in popularity during the height of COVID-19, many individuals still aren't aware that it's a viable option.
Latest:
Precision Prescribing Can Advance Mental Health TreatmentPharmacogenetics can inform precision prescribing practices, which in turn can solve the inefficiencies of current prescribing models.
Latest:
As Support for Medication Abortion Grows, Pharmacists Can Be Patient AdvocatesA conversation with Antonia Biggs, PhD, professor and acting director of the Advancing New Standards in Reproductive Health Program at the University of California, San Francisco.
Latest:
The Pharmacist-Developed Tool Helping Mitigate Drug ShortagesIn a world where drug shortages are one of the most pressing issues for pharmacy businesses, there are certain tools making a significant difference in helping patients access their drugs at the pharmacy.
Latest:
FDA Approves Oral Treatment for Postpartum DepressionLast August, zuranolone (Zurzuvae) became the first FDA-approved pill to treat postpartum depression in adults.
Latest:
Vaccine Update: FDA Approves Moderna COVID-19 VaccineSpikevax is now the second COVID-19 vaccine approved by regulators.
Latest:
Where PBM Reform is Headed in 2025, Beyond | NCPDP 2025Attorneys from The Phoenix Law Group joined Drug Topics at NCPDP 2025 to discuss the current state of pharmacy benefit manager reform and where it may end up in the near future.
Latest:
Navigating Pediatric ADHD Medication ShortagesStimulant medications are the first-line pharmacologic therapy for ADHD, but many of these medications are currently in short supply.
Latest:
Vaccines Show Efficacy, Safety in Preventing Diseases | APhA 2025Kelly Goode, PharmD, BCPS, FAPhA, FCCP, professor in the department of pharmacotherapy and outcomes science at Virginia Commonwealth University, discusses the current landscape of immunization recommendations.
Latest:
OTC Product Roundup: Sleep AidsWhether due to jet lag, stress, major life events, or something else, there are a lot of issues that can cause short-term insomnia. Send patients on their way to a better night’s sleep with these OTC sleep aid recommendations.
Latest:
Oncology Drug Exkivity to be Voluntarily Withdrawn From US MarketExkivity remains available while Takeda works with the FDA on withdrawal timing, and the company said that patients currently taking the therapy will continue to have access after it is withdrawn.
Latest:
Dry Eye Linked to Poor Sleep QualityAll components of sleep quality were reduced significantly in individuals with dry eye disease.
Latest:
Certain Factors May Increase Long COVID Risk in ChildrenChildren who tested positive were more likely to report long COVID symptoms at 90 days than children who tested negative.
Latest:
Now #Trending: Picking and Choosing Items to Stock the Front-EndTapping into nostalgia is one way to guide front-end stock choices.
Latest:
New Drug Review: FDA Approves Lazertinib Combination Therapy for Non–Small Cell Lung CancerStudy results show improvement in progression-free survival at 22 months.
Latest:
Texting Can Boost Revenue and Patient CareEight ways texting can improve patient retention and boost revenue.
Latest:
Sickle Cell Disease Finally Getting Its DueTwo possibly curative gene therapies for the disease, which disproportionately affects Black people, are under consideration by the FDA.
